Get the Stockscreener App
4.62
0.22%
-0.010
After Hours:
4.56
-0.06
-1.30%
Sagimet Biosciences Inc stock is traded at $4.62, with a volume of 582.15K.
It is down -0.22% in the last 24 hours and down -24.63% over the past month.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$4.63
Open:
$4.7
24h Volume:
582.15K
Relative Volume:
1.04
Market Cap:
$150.54M
Revenue:
$2.00M
Net Income/Loss:
$-51.04M
P/E Ratio:
-2.9259
EPS:
-1.579
Net Cash Flow:
$-45.65M
1W Performance:
-4.94%
1M Performance:
-24.63%
6M Performance:
-35.29%
1Y Performance:
+14.64%
1-Day Range:
$4.54
$4.875
1-Week Range:
$4.54
$5.03
52-Week Range:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
4.62 | 150.87M | 2.00M | -51.04M | -45.65M | -1.579 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results - Insider Monkey
Top 10 Stocks Under $5 That Could Triple - Insider Monkey
Aug Rallies: How does Sagimet Biosciences Inc score in quality rankingsRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - MSN
If You Invested $1,000 in Sagimet Biosciences Inc. (SGMT) - Stock Titan
Sagimet rises after denifanstat succeeds in late stage trial - MSN
Total debt per share of Sagimet Biosciences Inc. Class A – DUS:0O2 - TradingView
HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Q1 Earnings Forecast for SGMT Issued By HC Wainwright - MarketBeat
Citizens reiterates Sagimet Biosciences stock rating on MASH progress - Investing.com UK
Citizens reiterates Sagimet Biosciences stock rating on MASH progress By Investing.com - Investing.com Nigeria
Sagimet: Advancing FASN Inhibitor Pipeline and Solid Cash Position Support Buy Rating and $26 Target - TipRanks
Sagimet: Underappreciated, De-Risked Pipeline with Near-Term Milestones Supports Buy Rating - TipRanks
Sagimet Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oppenheimer reiterates Sagimet stock rating on MASH trial progress By Investing.com - Investing.com India
Oppenheimer reiterates Sagimet stock rating on MASH trial progress - Investing.com
Sagimet Biosciences Reports 2025 Financial Results, Advances MASH and Acne Clinical Programs with Denifanstat and Resmetirom Combination 14 - Minichart
Sagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC Wainwright - MarketBeat
Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating - TipRanks
Sagimet Biosciences Advances FASN Inhibitor Pipeline with Positive Phase 3 Results for Denifanstat in Acne and MASH Clinical Trials - Minichart
Sagimet Biosciences (NASDAQ:SGMT) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress - TipRanks
MASH and acne trial gains highlight Sagimet (NASDAQ: SGMT) 2025 update - Stock Titan
Sagimet Biosciences Q4 net loss narrows as R&D expenses fall - TradingView
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - The Manila Times
SGMT: Positive clinical progress in MASH and acne, with $113.1M cash and $51.0M net loss in 2025 - TradingView
Sagimet 10-K: Net Loss $51.0M, EPS $(1.58) - TradingView
Acne drug filing in China, new liver trial planned by Sagimet - Stock Titan
Sagimet Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday - MarketBeat
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. - Defense World
Bull Bear: How does Sagimet Biosciences Inc score in quality rankings2025 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn
SGMT Should I Buy - Intellectia AI
SGMT: Lead FASN inhibitor advances in MASH and acne, with pivotal trials and regulatory milestones ahead - TradingView
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - The Manila Times
Sagimet Biosciences to Participate in Upcoming Investor Conferences in March 2026 - Quiver Quantitative
Biotech Sagimet lines up three March investor conferences - Stock Titan
SGMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SGMTSagimet Biosciences Inc. Latest Stock News & Market Updates - Stock Titan
Sagimet (NASDAQ: SGMT) CMO receives 88,000-share option and 44,000 RSUs - Stock Titan
Sagimet Biosciences (SGMT) CFO awarded 88,000 options and 44,000 RSUs - Stock Titan
What is the long term forecast for Sagimet Biosciences Inc. stockChart Signals & Short-Term Swing Trade Alerts - mfd.ru
Can Sagimet Biosciences Inc. continue delivering strong returnsTrade Volume Report & Smart Money Movement Alerts - mfd.ru
Sagimet (SGMT) CEO granted 256k options and 128k RSUs in Form 4 - Stock Titan
Growth Value: Is Sagimet Biosciences Inc in a consolidation phaseJuly 2025 Retail & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):